Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.18632/ONCOTARGET.26541
P932PMC publication ID6349440
P698PubMed publication ID30719215

P2093author name stringLuigi Cavanna
Elena Orlandi
Chiara Citterio
P2860cites workCancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerQ29615679
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerQ29620913
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studiesQ35612977
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Q36250691
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Q40408396
Approaches to interpreting and choosing the best treatments in network meta-analysesQ42363950
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.Q47757890
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.Q51372253
Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluationQ51888144
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 StudyQ52640577
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant PatientsQ62661809
Network meta-analysis for indirect treatment comparisonsQ74720205
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerQ27853158
Measuring inconsistency in meta-analysesQ27860655
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectmeta-analysisQ815382
lung cancerQ47912
immunotherapyQ1427096
EGFR mutationQ28531504
P304page(s)209-215
P577publication date2019-01-04
P1433published inOncotargetQ1573155
P1476titleImmune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
P478volume10

Reverse relations

cites work (P2860)
Q99582721A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians
Q64922354Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Q89834907Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Q92740133Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Q90572119Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Q90283074Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

Search more.